

Phospho-CrkL (Tyr207) (G4) rabbit mAb FITC conjugate

www.abwizbio.com

Support: info@abwizbio.com

Order: sales@abwizbio.com

Catalog: #2093

Store at: 2-8°C

For Research Use Only. Not For Use In Diagnostic Procedures.


Applications
Flow Cytometry

Detection
N/A

Clonality
Monoclonal

Isotype
Rabbit IgGk

Format:	FITC
Cross Reactivity:	Predicted to work with mouse, rat and other homologues.
Formulation:	1X PBS, 0.09% NaN ₃ , 0.2% BSA
Preparation:	Protein A+G
Reactivity:	Human, Mouse
Recommended Usage:	For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.
Immunogen:	A synthetic phospho-peptide corresponding to residues surrounding Tyr207 of human phospho CrkL
Description:	CrkL (v-Crk sarcoma virus CT10 oncogene-like protein) is an adaptor protein composed of one Src Homology 2 (SH2) and two Src Homology 3 (SH3) domains separated by flexible linker sequences that act as building blocks to assemble multiprotein complexes (1). The Crk adaptor proteins (Crk and CrkL) constitute an integral part of a network of essential signal transduction pathways in humans and other organisms that act as major convergence points in tyrosine kinase signaling. CRKL is required for the normal development of multiple tissues that rely on fibroblast growth factor 8 (FGF8). Phosphorylation of Crk on Tyr 221 or CrkL on Tyr 207 causes intramolecular binding of the linker region to the SH2 domain, sequestering the SH2 and SH3N and preventing them from binding target proteins (2,3). Mounting evidence indicates that dysregulation of Crk proteins is associated with human diseases, including cancer and susceptibility to pathogen infections.
References:	<ol style="list-style-type: none">1. Ten Hoeve, J., et al., (1993). <i>Oncogene</i> 8:2469-2474.2. Rosen MK et al., (1995) <i>Nature</i> 1995, 374:477-479.3. Kobashigawa Y et al., (2007) <i>Nat Struct Mol Biol.</i> 14: 503-510.



Flow cytometric analysis of K562 cells unstained and treated with imatinib as negative control (blue) or treated imatinib (red) or treated with pervanadate (green) and stained using Phospho-CrkL (Tyr207) FITC conjugated antibody CrkLY207-G4. Cat. #2093.